416
Participants
Start Date
August 18, 2021
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
Denikitug
Administered Intravenously
Zimberelimab
Administered Intravenously
RECRUITING
National Taiwan University Hospital, Taipei
WITHDRAWN
Taipei Tzu Chi General Hospital, Taipei
RECRUITING
Changhua Christian Hospital, Changhua
RECRUITING
Chris O'Brien Lifehouse, Camperdown
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Monash Medical Centre, Clayton
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
MD Anderson Cancer Center, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital Universitario Quironsalud Madrid, Madrid
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital, Taoyuan
RECRUITING
Tennessee Oncology, PLLC, Nashville
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
University of Wisconsin Clinical Sciences Center, Madison
RECRUITING
Chi Mei Hospital, Liouying, Tainan City
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
NEXT Oncology, San Antonio
RECRUITING
University of California San Diego, La Jolla
RECRUITING
Stanford Cancer Center, Palo Alto
RECRUITING
National Taiwan University Cancer Center (NTUCC), Taipei
COMPLETED
Smilow Cancer Center, New Haven
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
University Health Network, Princess Margaret Cancer Centre, Toronto
RECRUITING
Hospital Universitari Vall d´Hebrón, Barcelona
Lead Sponsor
Gilead Sciences
INDUSTRY